ASH 2018 | iFCG for IGHV-mutated CLL in the frontline
Susan O’Brien, MD, of the University of California, Irvine, CA, provides an overview of the Phase II trial (NCT02629809) assessing the combination of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) as a frontline therapy for patients with IGHV-mutated chronic lymphocytic leukemia (CLL) vs. the current standard of care, FCR chemoimmunotherapy. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. O’Brien discusses the increased efficacy of this combination, allowing short-duration chemotherapy and minimizing potential toxicities, and also reveals the higher rates of undetectable MRD with the iFCG regimen.
Get great new content delivered to your inboxSign up
Warning: Invalid argument supplied for foreach() in /home/vjhemonc/public_html/wp-content/themes/vj/single.php on line 296